Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects

NCT01092832 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01092832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01092832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2010
Completion date
June 30, 2013
Enrollment
23 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

candidiasis